Complement-mediated acute effects of liposome-encapsulated hemoglobin

J. Szebeni, Carl R. Alving

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Recent studies on liposome-encapsulated hemoglobin (LEH) have indicated that this potential blood substitute can activate the complement (C) system of rats, pigs and man. The reaction can involve both the classical and the alternative pathways, and is mediated, in part, by the binding of natural anti-lipid antibodies to the lipid membrane of liposomes. The significance of these discoveries lies in the fact that C activation appears to be the primary cause of the acute physiological, hematological and laboratory changes that have been observed previously in rats and pigs following the administration of LEH or liposomes, which changes include pulmonary vasoconstriction with decreased cardiac output. In light of the proposed use of LEH as an emergency blood substitute, the latter impairment of cardiopulmonary function may warrant particular circumspection as it could aggravate the clinical state of trauma patients who are prone to develop respiratory distress partly as a consequence of C activation by the injury. Our studies on rats and pigs suggest that the above acute side effects of LEH, including the cardiopulmonary distress, can be efficiently inhibited with soluble complement receptor type I, a specific inhibitor of C activation.

Original languageEnglish
Pages (from-to)23-41
Number of pages19
JournalArtificial Cells, Blood Substitutes, and Immobilization Biotechnology
Volume27
Issue number1
Publication statusPublished - Jan 1999

Fingerprint

Liposomes
Hemoglobin
Hemoglobins
Blood substitutes
Blood Substitutes
Rats
Swine
Chemical activation
Complement Receptors
Wounds and Injuries
Membrane Lipids
Vasoconstriction
Antibodies
Cardiac Output
Lipids
Anti-Idiotypic Antibodies
Emergencies
Lung

ASJC Scopus subject areas

  • Biomedical Engineering
  • Hematology
  • Biotechnology
  • Biomaterials

Cite this

Complement-mediated acute effects of liposome-encapsulated hemoglobin. / Szebeni, J.; Alving, Carl R.

In: Artificial Cells, Blood Substitutes, and Immobilization Biotechnology, Vol. 27, No. 1, 01.1999, p. 23-41.

Research output: Contribution to journalArticle

@article{f3f79516d96f4e7780facd1746d23e1f,
title = "Complement-mediated acute effects of liposome-encapsulated hemoglobin",
abstract = "Recent studies on liposome-encapsulated hemoglobin (LEH) have indicated that this potential blood substitute can activate the complement (C) system of rats, pigs and man. The reaction can involve both the classical and the alternative pathways, and is mediated, in part, by the binding of natural anti-lipid antibodies to the lipid membrane of liposomes. The significance of these discoveries lies in the fact that C activation appears to be the primary cause of the acute physiological, hematological and laboratory changes that have been observed previously in rats and pigs following the administration of LEH or liposomes, which changes include pulmonary vasoconstriction with decreased cardiac output. In light of the proposed use of LEH as an emergency blood substitute, the latter impairment of cardiopulmonary function may warrant particular circumspection as it could aggravate the clinical state of trauma patients who are prone to develop respiratory distress partly as a consequence of C activation by the injury. Our studies on rats and pigs suggest that the above acute side effects of LEH, including the cardiopulmonary distress, can be efficiently inhibited with soluble complement receptor type I, a specific inhibitor of C activation.",
author = "J. Szebeni and Alving, {Carl R.}",
year = "1999",
month = "1",
language = "English",
volume = "27",
pages = "23--41",
journal = "Artificial Cells, Nanomedicine and Biotechnology",
issn = "2169-1401",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Complement-mediated acute effects of liposome-encapsulated hemoglobin

AU - Szebeni, J.

AU - Alving, Carl R.

PY - 1999/1

Y1 - 1999/1

N2 - Recent studies on liposome-encapsulated hemoglobin (LEH) have indicated that this potential blood substitute can activate the complement (C) system of rats, pigs and man. The reaction can involve both the classical and the alternative pathways, and is mediated, in part, by the binding of natural anti-lipid antibodies to the lipid membrane of liposomes. The significance of these discoveries lies in the fact that C activation appears to be the primary cause of the acute physiological, hematological and laboratory changes that have been observed previously in rats and pigs following the administration of LEH or liposomes, which changes include pulmonary vasoconstriction with decreased cardiac output. In light of the proposed use of LEH as an emergency blood substitute, the latter impairment of cardiopulmonary function may warrant particular circumspection as it could aggravate the clinical state of trauma patients who are prone to develop respiratory distress partly as a consequence of C activation by the injury. Our studies on rats and pigs suggest that the above acute side effects of LEH, including the cardiopulmonary distress, can be efficiently inhibited with soluble complement receptor type I, a specific inhibitor of C activation.

AB - Recent studies on liposome-encapsulated hemoglobin (LEH) have indicated that this potential blood substitute can activate the complement (C) system of rats, pigs and man. The reaction can involve both the classical and the alternative pathways, and is mediated, in part, by the binding of natural anti-lipid antibodies to the lipid membrane of liposomes. The significance of these discoveries lies in the fact that C activation appears to be the primary cause of the acute physiological, hematological and laboratory changes that have been observed previously in rats and pigs following the administration of LEH or liposomes, which changes include pulmonary vasoconstriction with decreased cardiac output. In light of the proposed use of LEH as an emergency blood substitute, the latter impairment of cardiopulmonary function may warrant particular circumspection as it could aggravate the clinical state of trauma patients who are prone to develop respiratory distress partly as a consequence of C activation by the injury. Our studies on rats and pigs suggest that the above acute side effects of LEH, including the cardiopulmonary distress, can be efficiently inhibited with soluble complement receptor type I, a specific inhibitor of C activation.

UR - http://www.scopus.com/inward/record.url?scp=0033001741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033001741&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 23

EP - 41

JO - Artificial Cells, Nanomedicine and Biotechnology

JF - Artificial Cells, Nanomedicine and Biotechnology

SN - 2169-1401

IS - 1

ER -